The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Department of Defense, are developing the vaccine as well as leading one of the trials. WRAIR also is co-funding the trials together with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The results will appear on Dec. 4 in the Lancet.
Related market report: Zika Virus Preparedness Market
“A vaccine is urgently needed to help prevent Zika infection, which can cause birth defects and other developmental abnormalities in babies born to infected women, as well as a constellation of other health problems in infected adults and children,” says NIAID Director Anthony S. Fauci, M.D. “We are encouraged by initial clinical trial results that indicate the ZPIV vaccine is safe and immunogenic, data that support additional clinical testing of the vaccine to determine its ability to prevent Zika virus infection.”
The ZPIV vaccine candidate contains whole Zika virus particles that have been inactivated and therefore cannot replicate and cause disease in humans. However, because the protein shell of the inactivated virus remains intact, it can be recognized by the immune system.
Of the 67 adult participants in the initial studies, 55 received the investigational vaccine and 12 received a placebo. The investigational vaccine was administered with an adjuvant (a compound that helps induce a stronger immune response) containing aluminum salts. All participants received two intramuscular injections of the same dose four weeks apart. The trial was double-blinded, meaning neither the investigators nor the participants knew who received a placebo.
Investigators tested participants’ blood samples periodically and detected antibodies to Zika virus in more than 90 percent of individuals who received the experimental vaccine, within four weeks after the last dose.
While Zika experts have not precisely determined the concentration of antibodies needed to protect against congenital infection, animal model studies are helping to provide useful insights. Researchers investigated the possible mechanism of vaccine protection by transferring the vaccinated participants’ antibodies into mice and then purposely infecting the mice with Zika virus. Results indicate the antibodies provided robust protection against Zika viremia (detectable virus in the blood).
“Zika remains a threat to U.S. military personnel and families of service members. We aim to develop a vaccine to protect the military, as well as the global community,” said Col. Nelson Michael, Zika program leader at the Walter Reed Army Institute of Research.
The vaccinations were administered at three sites: the WRAIR Clinical Trial Center in Silver Spring, Maryland; the Center for Virology and Vaccine Research, part of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston; and the Center for Vaccine Development at the Saint Louis University School of Medicine, a NIAID-funded Vaccine and Treatment Evaluation Unit (VTEU). The VTEU network can rapidly enroll large cohorts of volunteers and has conducted hundreds of clinical trials, many of which have contributed to vaccine licensure.
Additional research on the candidate vaccine will examine dosing, schedule and prior immunity. Specifically, WRAIR is examining the impact of pre-existing immunity by vaccinating participants with a yellow fever or Japanese encephalitis vaccine before beginning the ZPIV vaccine regimen. Those viruses, like Zika, are members of the flavivirus family. An additional study at Ponce Health Sciences University in Puerto Rico includes participants who already have been exposed naturally to a flavivirus, such as dengue. Saint Louis University seeks to identify the optimal ZPIV vaccine dose by assigning participants to receive a high, moderate or low dose , whereas Beth Israel Deaconess Medical Center is testing various dosing schedules.
NIAID is developing additional Zika vaccine candidates, including an experimental DNA vaccine, which is currently in Phase 2 trials at sites in the United States, Central, and South America. In addition, NIAID is helping to develop an investigational mRNA Zika vaccine (a gene-based platform similar to DNA vaccines) and a live-attenuated vaccine candidate designed to protect against Zika and all four strains of dengue virus.
More information about the Phase 1 trials of ZPIV can be found at ClinicalTrials.gov under the following identifiers: NCT02963909, NCT02952833, NCT02937233, and NCT03008122.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.